Truist lowered the firm’s price target on Progyny to $33 from $37 and keeps a Buy rating on the shares. The anlayst cites the company’s below-consensus Q2 results, with the management also lowering its revenue and EBITDA outlook for FY24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- The Broken Brown Egg and Progyny Announce the 2024 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building
- Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report
- Shopify upgraded, Reddit downgraded: Wall Street’s top analyst calls
- Progyny initiated with an Outperform at JMP Securities
- Progyny, Inc. to Host 2024 Inaugural Investor Day